A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany
A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany (BMC).
Clostridioides difficile infection (CDI) is one of the leading nosocomial infections, resulting in increased hospital length of stay and additional treatment costs. Bezlotoxumab, the first monoclonal antibody against CDI, has an 1 A guideline recommendation for prevention of CDI, after randomized clinical trials demonstrated its superior efficacy vs. placebo.
[...]
Conclusions
The study demonstrated administration of SoC + bezlotoxumab in patients at high
risk of CDI recurrence is cost-saving from a hospital management perspective.
Reduced length of stay in bezlotoxumab treated patients creates free spatial
and personnel capacities for the treating hospital. Yet, a requirement for
hospitals to administer bezlotoxumab is the previously made request for
additional fees and a successful price negotiation.
Quelle: BMC, 09.09.2021
